GlassScriptPhysician profile
Jerry W Smartt
NPI 1306850722
$253,512.38
in general payments reported to CMS, 2019-2025
65 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,344 · 2020: $19K · 2021: $33K · 2022: $77K · 2023: $32K · 2024: $43K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Food and Beverage: $12K · Consulting Fee: $6,865 · Travel and Lodging: $1,674 · Education: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,120.00 |
| Food and Beverage | $11,846.79 |
| Consulting Fee | $6,865.00 |
| Travel and Lodging | $1,673.92 |
| Education | $518.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169,200.35 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Biohaven Pharmaceutical Holding Company LTD. | $22,407.63 | 2022 | |
| Allergan, INC. | $20,673.94 | 2019-2021 | |
| Pfizer INC. | $9,503.51 | 2019-2025 | |
| Genentech USA, INC. | $6,891.20 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $4,317.36 | 2020-2021 | |
| Livanova USA, INC. | $2,623.88 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $1,569.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,274.30 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $1,136.87 | 2019-2025 | Mavenclad, Mavenclad |
| Harmony Biosciences LLC | $1,063.45 | 2020-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $942.64 | 2019-2025 | |
| Ucb, INC. | $913.07 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Eisai INC. | $741.57 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $683.07 | 2019-2025 | Nuplazid, Daybue |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $665.94 | 2024-2025 | Fanapt, Ponvory, Hetlioz |
| Mdd US Operations, LLC | $619.45 | 2019-2025 | Apokyn, Apokyn |
| Axsome Therapeutics, INC. | $605.46 | 2023-2025 | Sunosi, Symbravo, Auvelity |
| Lundbeck LLC | $590.71 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $565.44 | 2019-2025 | Kisunla, Emgality, Zepbound |
| Supernus Pharmaceuticals, INC. | $534.43 | 2019-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $506.36 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $419.83 | 2019-2023 | |
| Argenx US, INC. | $418.83 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $396.70 | 2019-2022 | |
| Sk Life Science, INC. | $390.60 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $354.17 | 2019-2025 | Crexont, Rytary |
| Csl Behring | $322.34 | 2019-2025 | Hizentra |
| Janssen Pharmaceuticals, INC | $309.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $300.59 | 2020-2023 | Belsomra, Lagevrio |
| Jazz Pharmaceuticals INC. | $209.16 | 2019-2024 | |
| Biogen, INC. | $184.67 | 2021-2024 | Vumerity, Avonex, Tysabri |
| Celgene Corporation | $179.35 | 2022-2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $153.15 | 2019-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $140.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.64 | 2024-2025 | Hyqvia, Trintellix |
| Arbor Pharmaceuticals, INC. | $132.98 | 2019-2022 | |
| Daiichi Sankyo INC. | $128.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $123.32 | 2019-2025 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $103.79 | 2025 | Zeposia |
| Avanir Pharmaceuticals, INC. | $93.78 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $92.56 | 2019-2022 | |
| Tanabe Pharma America, INC. | $91.78 | 2024-2025 | Radicava |
| Almatica Pharma LLC | $81.05 | 2021 | |
| Sumitomo Pharma America, INC. | $63.61 | 2023 | Aptiom |
| Aprecia Pharmaceuticals, LLC | $52.51 | 2021-2023 | Spritam |
| Ironshore Pharmaceuticals INC. | $52.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.72 | 2020-2023 | Relistor |
| Bausch Health US, LLC | $51.13 | 2019-2020 | |
| Tg Therapeutics, INC. | $50.71 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $47.91 | 2020-2024 | |
| Merz Pharmaceuticals, LLC | $42.67 | 2025 | Inbrija |
| Neurelis, INC. | $40.95 | 2021 | |
| Genentech, INC. | $39.95 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $32.99 | 2024 | Lumryz |
| Grt US Holding, INC. | $26.03 | 2022 | |
| Assertio Therapeutics, INC. | $24.72 | 2019 | |
| Abbott Laboratories | $24.15 | 2025 | Infinity |
| Promius Pharma LLC | $22.47 | 2019 | |
| Banner Life Sciences, LLC | $19.90 | 2023 | |
| Octapharma USA, INC. | $16.67 | 2025 | Panzyga |
| Collegium Pharmaceutical, INC. | $16.59 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.52 | 2020 | |
| Avion Pharmaceuticals | $14.56 | 2022 | |
| Zyla Life Sciences, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Smartt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.